GSA Capital Partners LLP Takes $235,000 Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

GSA Capital Partners LLP acquired a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) in the 3rd quarter, HoldingsChannel.com reports. The fund acquired 5,873 shares of the company’s stock, valued at approximately $235,000.

A number of other hedge funds have also recently bought and sold shares of HRMY. LSV Asset Management boosted its position in shares of Harmony Biosciences by 72.5% during the 2nd quarter. LSV Asset Management now owns 578,246 shares of the company’s stock valued at $17,446,000 after purchasing an additional 243,100 shares in the last quarter. American Century Companies Inc. grew its position in Harmony Biosciences by 53.7% in the second quarter. American Century Companies Inc. now owns 681,536 shares of the company’s stock worth $20,562,000 after buying an additional 238,140 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Harmony Biosciences by 56.7% in the second quarter. Renaissance Technologies LLC now owns 595,800 shares of the company’s stock valued at $17,975,000 after buying an additional 215,700 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Harmony Biosciences by 145.4% during the 2nd quarter. Marshall Wace LLP now owns 305,612 shares of the company’s stock valued at $9,220,000 after acquiring an additional 181,092 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Harmony Biosciences by 1,011.7% during the 1st quarter. Janus Henderson Group PLC now owns 185,083 shares of the company’s stock worth $6,214,000 after acquiring an additional 168,434 shares in the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Jeffrey Dierks sold 21,496 shares of the business’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total transaction of $869,943.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 30.80% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. UBS Group initiated coverage on shares of Harmony Biosciences in a report on Tuesday, September 10th. They set a “buy” rating and a $56.00 price target on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $59.00 target price (up previously from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Mizuho increased their price target on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, October 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $52.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, October 29th. Finally, Cantor Fitzgerald increased their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Two investment analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $47.00.

Harmony Biosciences Price Performance

Shares of Harmony Biosciences stock opened at $34.07 on Monday. Harmony Biosciences Holdings, Inc. has a 1-year low of $28.14 and a 1-year high of $41.61. The firm has a fifty day simple moving average of $35.53 and a 200-day simple moving average of $33.56. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of 16.15, a PEG ratio of 0.62 and a beta of 0.77.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company had revenue of $186.00 million for the quarter, compared to the consensus estimate of $184.07 million. During the same period last year, the business posted $0.63 earnings per share. The firm’s revenue was up 16.0% compared to the same quarter last year. On average, sell-side analysts expect that Harmony Biosciences Holdings, Inc. will post 2.36 earnings per share for the current year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.